CytoSorbents Corporation (CTSO)

[Bsbs12]

In just 10 months at the head of Germany's Fresenius, Chief Executive Officer Stephan Sturm has now inked the health-care provider's two biggest-ever deals.

With the $4.3 billion acquisition of Lake Forest-based generic drugmaker Akorn, announced late Monday, Fresenius will get a stronger foothold in the U.S., with access to a network of retail pharmacies and outpatient clinics as well as the hospitals where it has traditionally marketed its products. Akorn will complement Fresenius' Kabi medicines unit, which specializes in intravenous drugs.